January 2026
MDMA
What January 2026's 23 new studies found, synthesized from the papers below. All MDMA research →
The synthesis
Synthesized from 8 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, then ranked by relevance.
Research on MDMA in January 2026 shows mixed findings: while MDMA-assisted therapy shows promise for PTSD and social anxiety, a case report documents new-onset OCD after treatment, and an open-label pilot found small, non-significant changes in inflammatory biomarkers. A review highlights that MDMA has not been approved for medical use due to lack of clear neurobiological insight, and a cross-sectional analysis reveals inconsistencies in protocol and adverse event reporting across clinical trials, undermining credibility and safety evaluation.
Confidence in the evidence
Low-Moderate- Only one small open-label pilot (n=23) examined inflammatory biomarkers, with small effect sizes and wide confidence intervals.
- A single case report describes new-onset OCD after MDMA-assisted therapy, but no controlled studies assess this risk.
- A cross-sectional analysis of 336 trials found major inconsistencies in protocol registration and adverse event reporting, raising concerns about data quality.
- The evidence base is heterogeneous, including reviews, case reports, observational studies, and one pilot, with no large RCTs published in this period.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Empathic Behavioral Substrates Altered by MDMA and Their Therapeutic Consequences 2026 | review | Unclear | This review concludes that MDMA's therapeutic potential is unclear due to lack of clear insight into its neurobiological effects, particularly regarding social behavior. | |
| Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin. 2026 | cross-sectional analysis | 336 | Opposes | This analysis found major inconsistencies in protocol registration and adverse event reporting across MDMA and psilocybin trials, with only 3 of 29 trials showing full concordance in adverse event reporting. |
| Inflammatory biomarker outcomes associated with MDMA-assisted therapy: an open-label exploratory study. 2026 | open-label pilot study | 23 | Mixed | This pilot found small increases in IL-6 and CRP and a small decrease in TNF-α after MDMA-assisted group therapy, with no significant changes; baseline IL-6 and TNF-α were positively associated with PTSD severity. |
| New‐Onset Obsessive–Compulsive Symptoms After MDMA‐Assisted Psychotherapy in a Patient With Refractory PTSD: A Case Report 2026 | case report | 1 | Opposes | This case report describes new-onset obsessive-compulsive disorder following MDMA-assisted psychotherapy, with symptoms persisting for over a year. |
| Investigating the Role of Self-Compassion in MDMA-Assisted Therapy for Social Anxiety Disorder 2026 | theoretical/protocol | Unclear | This article outlines a study protocol to investigate self-compassion as a mechanism of MDMA-assisted therapy for social anxiety disorder, but no results are reported. | |
| Psychedelic therapeutics in psychiatric conditions 2026 | review | Unclear | This review notes that no psychedelic treatments, including MDMA, have been approved for any psychiatric condition, and the one large MDMA development program was disapproved by the FDA. | |
| Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants. 2026 | RCT | 23 | Mixed | This double-blind crossover trial found that MDA produced stronger and longer-lasting subjective effects than MDMA, including more negative effects, while lysine-MDMA showed no detectable MDMA in blood and no effects. |
| The entactogen MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") disrupts helping behaviour while reinforcing electrophysiological indicators of potentially associated synaptic plasticity in male Sprague-Dawley rats. 2026 | preclinical | Opposes | This preclinical study found that MDMA at higher doses (5 and 10 mg/kg) fully suppressed helping behavior in rats, contrary to the hypothesis that MDMA enhances prosocial behavior. |
This review concludes that MDMA's therapeutic potential is unclear due to lack of clear insight into its neurobiological effects, particularly regarding social behavior.
review
This analysis found major inconsistencies in protocol registration and adverse event reporting across MDMA and psilocybin trials, with only 3 of 29 trials showing full concordance in adverse event reporting.
cross-sectional analysis Sample size: 336
This pilot found small increases in IL-6 and CRP and a small decrease in TNF-α after MDMA-assisted group therapy, with no significant changes; baseline IL-6 and TNF-α were positively associated with PTSD severity.
open-label pilot study Sample size: 23
This case report describes new-onset obsessive-compulsive disorder following MDMA-assisted psychotherapy, with symptoms persisting for over a year.
case report Sample size: 1
This article outlines a study protocol to investigate self-compassion as a mechanism of MDMA-assisted therapy for social anxiety disorder, but no results are reported.
theoretical/protocol
This review notes that no psychedelic treatments, including MDMA, have been approved for any psychiatric condition, and the one large MDMA development program was disapproved by the FDA.
review
This double-blind crossover trial found that MDA produced stronger and longer-lasting subjective effects than MDMA, including more negative effects, while lysine-MDMA showed no detectable MDMA in blood and no effects.
RCT Sample size: 23
This preclinical study found that MDMA at higher doses (5 and 10 mg/kg) fully suppressed helping behavior in rats, contrary to the hypothesis that MDMA enhances prosocial behavior.
preclinical
Points of agreement
- MDMA-assisted therapy is being investigated for PTSD and social anxiety, but no approved treatments exist.
- There are concerns about data quality and safety reporting in MDMA clinical trials.
- MDMA's effects on social behavior and empathy are complex and not fully understood.
Conflicts
- MDMA is hypothesized to enhance prosocial behavior, but a preclinical study found it suppressed helping behavior in rats.
- MDMA-assisted therapy shows promise for PTSD, but a case report documents new-onset OCD after treatment.
- Inflammatory biomarker changes were small and non-significant in one pilot, but baseline inflammation was linked to PTSD severity.
Gaps
- No large, well-controlled RCTs on MDMA-assisted therapy were published in this period.
- Durability of therapeutic effects and long-term safety remain unstudied.
- Mechanisms of action, particularly neurobiological and immunological, are poorly understood.
- Risk of adverse psychiatric outcomes (e.g., OCD) is not systematically assessed.
- Blinding and placebo control remain challenging in psychedelic trials.